Compare GSK plc (GSK) vs Marriott International Inc (MAR) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Marriott International (MAR) trades at $371.50, up 2.29% today, with a bearish technical signal despite recent earnings beats. The company maintains strong revenue growth, reaching $26.19B in 2025, with a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and reaching 10,000 global properties. Analyst consensus is mixed with 44% buy ratings but a price target of $387.33 suggesting modest upside potential.

MAR shows solid operational performance with consistent cash flow generation, though high debt levels and negative shareholder equity present risks. The stock faces headwinds from technical bearish signals and hotel owner disputes over loyalty programs. Upside potential exists from travel recovery and strategic partnerships, but investors should weigh valuation concerns against growth prospects.